Opus Genetics IRD Net investment gains (losses)
Net investment gains (losses) at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnDerivativeInstrumentsNetPretax.
The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's net investment gains (losses).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's net investment gains (losses)?
- Opus Genetics (IRD) reported net investment gains (losses) of -$51.36M in Q1 2026.
- How has Opus Genetics's net investment gains (losses) changed year-over-year?
- Opus Genetics's net investment gains (losses) decreased by 1931.2% year-over-year, from $2.81M to -$51.36M.
- What is the long-term trend for Opus Genetics's net investment gains (losses)?
- Over 4 years (2021 to 2025), Opus Genetics's net investment gains (losses) has grown at a -23.6% compound annual growth rate (CAGR), from -$33.83M to -$11.52M.
- What does net investment gains (losses) mean?
- Net realized and unrealized gains and losses on the company's investment portfolio, including equity securities, debt securities, and alternative investments.